Answer

No, you should not take Tyrosine while using a Monoamine Oxidase Inhibitor (MAOI). This combination is contraindicated due to the risk of a life-threatening hypertensive crisis.

Evidence Assessment

Quality Score: 95 (Tier A) The evidence for this interaction is considered strong and well-established based on fundamental pharmacological principles of catecholamine metabolism and FDA drug labeling guidelines.

Clinical Evidence

Tyrosine is a direct amino acid precursor to L-dopa, which is then converted into dopamine, norepinephrine, and epinephrine (catecholamines). Under normal physiological conditions, MAO enzymes break down these catecholamines to maintain homeostasis.

MAOIs inhibit the enzyme responsible for this degradation. When Tyrosine is supplemented in the presence of an MAOI, the increased production of catecholamines cannot be cleared from the system. This leads to an accumulation of norepinephrine and dopamine in the synaptic cleft, which can trigger a massive increase in blood pressure, known as a hypertensive crisis [Cooper AJ. Biol Psychiatry 1989].

Practical Guidance

Due to the severity of the interaction, there is no "safe" dosage or timing window for combining these two substances. - Populations at Risk: Individuals taking non-selective MAOIs (e.g., phenelzine, tranylcypromine) or selective MAO-A inhibitors are at the highest risk. - Duration: Because MAOIs irreversibly or semi-permanently inhibit the enzyme, a significant washout period (typically 2 weeks) is required after stopping an MAOI before Tyrosine supplementation can be safely considered.

Safety & Interactions

Contraindication: NO (Absolute Contraindication)

• Drug Class: Monoamine Oxidase Inhibitors (MAOIs).
• Mechanism: Synergistic increase in catecholamine levels; Tyrosine increases the "substrate" (precursor) while the MAOI blocks the "drain" (metabolism).
• Clinical Risk: This combination can lead to a hypertensive crisis, characterized by severe headache, palpitations, and dangerously high blood pressure, which may result in stroke or death.
• Clinical Management: Absolutely avoid the combination. If a patient is transitioning from an MAOI to a supplement regimen, ensure the drug has been fully cleared from the system according to the prescribing physician's guidance.
• High-Risk Populations: Individuals with pre-existing hypertension, cardiovascular disease, or those taking other sympathomimetic agents should exercise extreme caution.